[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531911":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":22,"studyPopulation":23,"armGroups":18,"interventions":18,"overallOfficials":18,"centralContacts":24,"locations":30,"responsibleParty":122,"collaborators":18,"id":124,"slug":125,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":126,"sex":132,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":18,"studyType":138,"phases":18,"briefSummary":139,"conditions":140,"keywords":18,"overallStatus":33,"whyStopped":18,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Mortality at 24 months by stage","Mortality at 24 months by stage will be evaluated","24 months from diagnosis",[14],{"measure":15,"description":16,"timeFrame":17},"Rate of hematologic relapse in Complete Response patients at 2 years by MRD status","Rate of hematologic relapse in Complete Response patients at 2 years by MRD status will be evaluated","2 years from diagnosis",null,{"allocation":18,"interventionModel":18,"interventionModelDescription":18,"primaryPurpose":18,"observationalModel":20,"timePerspective":21,"maskingInfo":18},"COHORT","PROSPECTIVE","In the frame of the EUREKA Consortium, a patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers across Europe or at their satellite sites will be created, in association with a cross-border biorepository and sample sharing network for the study of both disease-causing light chains and plasma cells with advanced molecular technologies. A dedicated site will support the Consortium with big data analysis and artificial intelligence applied to health. The aims are: 1) Defining the impact of advanced molecular technologies to promote early diagnosis and guide therapeutic choices; 2) describing the natural history of the disease in a representative cohort of AL patients in the contemporary era of effective anti-plasma cell therapies; 3) investigating and refining novel advanced technologies to detect with high sensitivity residual disease-causing plasma cells\u002Flight chains in patients achieving a complete hematologic response to therapy (minimal residual disease, MRD).","400 patients with AL amyloidosis will be enrolled at diagnosis and evaluated at any of the participating clinical centers.",[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Giovanni Palladini","CONTACT","+390382502994","segreteria.amiloidosi@smatteo.pv.it",[31,51,67,81,95,106],{"facility":32,"status":33,"city":34,"state":18,"zip":18,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Medical Department, Amyloidosis Center, University Hospital, Im Neuenheimer Feld 672","RECRUITING","Heidelberg","Germany","DE",{"type":38,"coordinates":39},"Point",[40,41],8.69079,49.40768,{"lat":41,"lon":40},[44,46,48],{"name":45,"role":27,"phone":18,"phoneExt":18,"email":18},"Stefan Schönland, MD",{"name":45,"role":47,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"name":49,"role":50,"phone":18,"phoneExt":18,"email":18},"Ute Hegenbart, MD","SUB_INVESTIGATOR",{"facility":52,"status":33,"city":53,"state":18,"zip":18,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Fondazione IRCCS Policlinico San Matteo, Pavia, Viale Golgi 19, 27100","Pavia","Italy","IT",{"type":38,"coordinates":57},[58,59],9.15917,45.19205,{"lat":59,"lon":58},[62,63,65],{"name":26,"role":27,"phone":18,"phoneExt":18,"email":18},{"name":64,"role":47,"phone":18,"phoneExt":18,"email":18},"Giovanni Palladini, MD, PhD",{"name":66,"role":50,"phone":18,"phoneExt":18,"email":18},"Mario Ulisse Nuvolone, MD, PhD",{"facility":68,"status":33,"city":69,"state":18,"zip":18,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"UMC Utrecht, dept Hematology, Amyloid Expertise Center, Utrecht, Heidelberglaan","Utrecht","Netherlands","NL",{"type":38,"coordinates":73},[74,75],5.12222,52.09083,{"lat":75,"lon":74},[78,80],{"name":79,"role":27,"phone":18,"phoneExt":18,"email":18},"Monique Minnema, MD",{"name":79,"role":47,"phone":18,"phoneExt":18,"email":18},{"facility":82,"status":33,"city":83,"state":18,"zip":18,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Instituto de Investigación Sanitaria de Navarra (IdiSNA) C. de Irunlarrea, 3, 31008 Pamplona, Navarra","Pamplona","Spain","ES",{"type":38,"coordinates":87},[88,89],-1.64323,42.81687,{"lat":89,"lon":88},[92,94],{"name":93,"role":27,"phone":18,"phoneExt":18,"email":18},"Bruno Paiva, PhD",{"name":93,"role":47,"phone":18,"phoneExt":18,"email":18},{"facility":96,"status":97,"city":98,"state":18,"zip":18,"country":99,"countryCode":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":18},"University of Applied Sciences and Arts Northwestern Switzerland, Institute of Medical Engineering and Medical Informatics","ACTIVE_NOT_RECRUITING","Muttenz","Switzerland","CH",{"type":38,"coordinates":102},[103,104],7.64511,47.52271,{"lat":104,"lon":103},{"facility":107,"status":33,"city":108,"state":18,"zip":18,"country":109,"countryCode":110,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Universidad de la Republica Hospital de Clinicas \"Dr Manuel Quintela\"","Montevideo","Uruguay","UY",{"type":38,"coordinates":112},[113,114],-56.18816,-34.90328,{"lat":114,"lon":113},[117,121],{"name":118,"role":27,"phone":119,"phoneExt":18,"email":120},"Eloisa Riva, MD","+59819534637","eriva@hc.edu.uy",{"name":118,"role":47,"phone":18,"phoneExt":18,"email":18},{"type":47,"investigatorFullName":26,"investigatorTitle":123,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"MD, PhD","100531911","a-european-registry-and-sample-sharing-network-to-promote-the-diagnosis-and-management-of-light-chain-amyloidosis-eureka-100531911",false,"NCT06205953","A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)","Bonding Molecular Genotyping and Phenotyping to Outcome Measures in AL Amyloidosis: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)","EUREKA","Inclusion Criteria:\n\n* diagnosis of systemic AL amyloidosis;\n* treatment-naïve;\n* age ≥18 years;\n* ability to understand and willingness to sign an informed consent;\n* planned follow-up at participating center.\n\nExclusion Criteria:\n\n* non-AL amyloidosis;\n* previous treatment for AL amyloidosis.","ALL","18 Years","99 Years",{"count":136,"type":137},400,"ESTIMATED","OBSERVATIONAL","A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.",[141],"AL Amyloidosis","2026-04-13",{"date":144,"type":145},"2026-04-16","ACTUAL",{"date":147,"type":145},"2024-01-01",{"date":149,"type":137},"2026-06-01",{"name":5,"class":6},6]